Nicox S.A.
Ophthalmology company developing therapies based on a nitric oxide-donating platform.
COX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013018124 (+6 more)
- LEI:
- 969500EZGEO9W4JXR353
- Country:
- France
- Address:
- SOPHIA, 06410 BIOT
- Website:
- https://www.nicox.com/
Description
Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-23 07:30 |
Nicox : Résultats financiers du premier semestre 2025
|
French | 227.0 KB | ||
| 2025-10-23 07:30 |
Nicox Provides First Half 2025 Financial Results
|
English | 216.7 KB | ||
| 2025-10-02 07:30 |
Nicox annonce que NCX 470 a démontré une efficacité soutenue jusqu’à 12 mois da…
|
French | 178.3 KB | ||
| 2025-10-02 07:30 |
Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Cli…
|
English | 167.2 KB | ||
| 2025-09-04 07:30 |
Nicox prévoit de rembourser intégralement ses dettes financières, NCX 470 ayant…
|
French | 217.6 KB | ||
| 2025-09-04 07:30 |
Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globall…
|
English | 188.1 KB | ||
| 2025-08-26 07:30 |
Nicox annonce la mise en ligne d’une page « Questions-Réponses » sur son site i…
|
French | 155.8 KB | ||
| 2025-08-26 07:30 |
Nicox Announces Shareholder Q&A Webpage Available
|
English | 153.6 KB | ||
| 2025-08-12 15:53 |
Franchissement de seuils
|
French | 113.6 KB | ||
| 2025-08-08 07:30 |
Nicox Extends Existing Flexible Equity Financing
|
English | 181.9 KB | ||
| 2025-08-05 07:30 |
Nicox annonce l’initiation par son partenaire Kowa d’un essai clinique de Phase…
|
French | 176.0 KB | ||
| 2025-08-05 07:30 |
Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan
|
English | 171.5 KB | ||
| 2025-06-30 07:30 |
Nicox annonce que le dernier patient a terminé l’essai clinique de Phase 3 Dena…
|
French | 161.2 KB | ||
| 2025-06-30 07:30 |
Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial
|
English | 156.1 KB | ||
| 2025-06-06 07:30 |
Nicox : Convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 27 ju…
|
French | 184.6 KB |
Automate Your Workflow. Get a real-time feed of all Nicox S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nicox S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nicox S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
